Students gave 69 poster presentations and 24 oral presentations at the University of North Georgia's (UNG) 30th Annual ...

Azenosertib is positioned as a potentially first-in-class and best-in-class WEE1 inhibitor ... that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical ...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...